OWCP (OWC Pharmaceutical Research) 6-Month Share Buyback Ratio : 0.00% (As of Sep. 2019 )

View and export this data going back to 2008. Start your Free Trial

What is OWC Pharmaceutical Research 6-Month Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. OWC Pharmaceutical Research's current 6-Month Share Buyback Ratio was 0.00%.

Competitive Comparison of OWC Pharmaceutical Research's 6-Month Share Buyback Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, OWC Pharmaceutical Research's 6-Month Share Buyback Ratio, along with its competitors' market caps and 6-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OWC Pharmaceutical Research's 6-Month Share Buyback Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, OWC Pharmaceutical Research's 6-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where OWC Pharmaceutical Research's 6-Month Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

OWC Pharmaceutical Research 6-Month Share Buyback Ratio Calculation

OWC Pharmaceutical Research's 6-Month Share Buyback Ratio for the quarter that ended in Sep. 2019 is calculated as

6-Month Share Buyback Ratio	=	(Shares Outstanding (EOP) (Mar. 2019 )	-	Shares Outstanding (EOP) (Sep. 2019 ))	/	Shares Outstanding (EOP) (Mar. 2019 )
	=	(176.001	-	244.478)	/	176.001
	=	-38.91%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OWC Pharmaceutical Research (OTCPK:OWCP) 6-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

OWC Pharmaceutical Research 6-Month Share Buyback Ratio Related Terms

OWC Pharmaceutical Research Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » OWC Pharmaceutical Research Corp (OTCPK:OWCP) » Definitions » 6-Month Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Ben Gurion Street, Ramat Gan, ISR, 5257334

Website

http://www.owcpharma.com

OWC Pharmaceutical Research Corp is a medical cannabis research and development company. The firm through its subsidiary researches and develops cannabis-based products and treatments specifically designed for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder (PTSD), migraine, sexual function and skin disorders. It also provides consulting services to governmental and private entities to assist them with developing and implementing tailor-made medical cannabis program.

Executives

Asher Zwebner

director, officer: CHIEF FINANCIAL OFFICER

CDOOR CORPORATION, 20 A REHOV SHAREI TORAH BAYIT VEGAN, JERUSALEM L3 96387